医药行业专题报告:痛风市场潜力庞大 国产URAT1抑制剂百花齐放

民生证券股份有...
23 May

痛风及高尿酸血症患者规模上亿,现有药物销售额接近10 亿元,但副作用较多,提示存在较大的未满足的临床需求。痛风患病率正持续上升,年轻化趋势明显,我国成人居民高尿酸血症患病率为14%,痛风患病率为0.86%~2.20%,初步估算我国痛风患者约为1023~2618 万人,高尿酸血症患者约为1.67 亿人,患者人群庞大。当前痛风治疗主要依赖别嘌醇、非布司他、苯溴马隆等老一代降尿酸药物,该类药物在2020...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10